# EDGAR Filing Document

**Accession Number:** 0001648257
**File Stem:** 0001648257-25-000081
**Filing Date:** 2025-11
**Character Count:** 18656
**Document Hash:** 1ef8aae217fd94df684a70c0389fe620
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001648257-25-000081.hdr.sgml**: 20251128

**ACCESSION NUMBER**: 0001648257-25-000081

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 5

**CONFORMED PERIOD OF REPORT**: 20251128

**FILED AS OF DATE**: 20251128

**DATE AS OF CHANGE**: 20251128

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HUTCHMED (China) Ltd
- **CENTRAL INDEX KEY:** 0001648257
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37710
- **FILM NUMBER:** 251532270

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3
- **BUSINESS PHONE:** 852-2121-3888

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hutchison China MediTech Ltd
- **DATE OF NAME CHANGE:** 20150716

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 6-K**

------

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

**For the Month of November 2025**

**Commission File Number: 001-37710**

------

**HUTCHMED (CHINA) LIMITED**

(Translation of registrant's name into English)

------

**48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong**

(Address of principal executive offices)

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ◻

------

**HUTCHMED (CHINA) LIMITED**

**Form 6-K**

<u>EXHIBIT INDEX</u>

---

| | | |
|:---|:---|:---|
| **Exhibit No.** |  | **Description** |
| Exhibit 99.1 |  | **Press release relating to clinical data to be presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting**<br>|
| Exhibit 99.2 |  | Announcement relating to total voting rights |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| HUTCHMED (CHINA) LIMITED | HUTCHMED (CHINA) LIMITED |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |

---

Date: November 28, 2025

------

## Exhibit 99.1

**Exhibit 99.1**

![Graphic](hcm-20251128xex99d1001.gif)

**Press Release**

#### HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
**Hong Kong, Shanghai & Florham Park, NJ — Thursday, November 27, 2025:** HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology ("ESMO") Asia Congress 2025, taking place on December 5-7, 2025 in Singapore, and the American Society of Hematology ("ASH") Annual Meeting taking place on December 6-9, 2025 in Orlando, USA.

Results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, as well as from the phase II part of the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma, will be presented at the ESMO Asia Congress 2025. Results from the phase II part of the phase II/III study of surufatinib in combination with camrelizumab and chemotherapy as a first-line treatment for metastatic pancreatic cancer will also be reported. Details of the presentations are as follows:

---

| | | |
|:---|:---|:---|
| **Abstract title**<br><BORDER_TOP> | **Presenter/Lead author**<br><BORDER_TOP> | **Presentation details**<br><BORDER_TOP> |
| **ESMO Asia Congress 2025 - SPONSORED STUDIES** |  |  |
| **A first-in-human (FIH), dose escalation study of HMPL-A83 (A83), an anti-CD47 monoclonal antibody (mAb) in patients (pts) with advanced solid tumors**<br>| Ye Guo <br>(Shanghai, China) | 162MO \| Mini Oral session: Developmental therapeutics and precision medicine<br>Sunday, December 7, 2025<br>11:40 - 11:45 SGT<br>Hall 407 |
| **Fruquintinib monotherapy as second-line (2L) treatment in locally advanced or metastatic renal cell carcinoma (RCC): results from phase 2 part of FRUSICA-2** | Shanshan Wang <br>(Shanghai, China)<br>| 540O \| Proffered Paper session: Genitourinary tumours<br>Friday, December 5, 2025<br>14:55 - 15:05 SGT <br>Hall 402 |
| **Surufatinib (S) in combination with camrelizumab (C), nab-paclitaxel and gemcitabine (AG) as the first-line treatment in metastatic pancreatic cancer: results from phase 2 part of a randomized, open-label, active-controlled, phase 2/3 study** | Shukui Qin <br>(Nanjing, China)<br>| 375P \| Poster Display: Gastrointestinal tumours, non-colorectal |
| **Osimertinib (osi) + savolitinib (savo) in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) with MET overexpression and/or amplification (OverExp/Amp) following progressive disease (PD) on osi: SAVANNAH Asian subset** | Se-Hoon Lee <br>(Seoul, Korea)<br>| 982P \| Poster Display: <br>Thoracic tumours, metastatic |
| **Patient-relevant Outcomes (PROs) from SACHI: a Phase 3 Trial of Savolitinib (Savo) plus Osimertinib (Osi) versus Chemotherapy (Chemo) in EGFR-mutant (EGFRm) and MET-amplified (METamp) Advanced NSCLC after Progression on EGFR-TKIs** | Yongfeng Yu <br>(Shanghai, China)<br>| 984P \| Poster Display: <br>Thoracic tumours, metastatic |
| **Analysis of MET Amplification (METamp) with FISH and NGS Method in SACHI Trial** | Longhua Sun <br>(Nanchang, China) | 988P \| Poster Display: <br>Thoracic tumours, metastatic |
| **Progression pattern in patients (pts) with EGFR-mutant (EGFRm), MET-amplified (METamp) advanced NSCLC treated with savolitinib (savo) plus osimertinib (osi)** | Haiyan Yang <br>(Changsha, China)<br>| 1002P \| Poster Display: <br>Thoracic tumours, metastatic |
| **MET testing and treatment (tx) sequencing after progression of disease (PD) on first-line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): Final analysis of a global real-world (rw) study** | Julia Rotow <br>(Boston, US)<br>| 1005P \| Poster Display: <br>Thoracic tumours, metastatic |

---

------

---

| | | |
|:---|:---|:---|
| **Abstract title**<br><BORDER_TOP> | **Presenter/Lead author**<br><BORDER_TOP> | **Presentation details**<br><BORDER_TOP> |
| **<br>ESMO Asia Congress 2025 - INVESTIGATOR-INITIATED STUDIES** |  |  |
| **Fruquintinib Combined with TAS-102 with or without SBRT as Third- or Later-Line Treatment in Metastatic Colorectal Cancer: Preliminary Results from a Prospective Phase II Trial** | Chen Zhang/ Yi Wang<br>(Ningbo, China) | 205P \| Poster Display: Gastrointestinal tumours, colorectal |
| **Efficacy and safety of fruquintinib combined with PD-1 inhibitor and chidamide in MSS mCRC: a comparison with real-world bevacizumab plus anti-pd-1 and chidamide arm** | Guanghai Dai/ Miaomiao Gou<br>(Beijing, China)<br>| 245eP \| Poster Display: Gastrointestinal tumours, colorectal |
| **The Efficacy and Safety of Fruquintinib (F) Plus FOLFIRI as Second-line (2L) Treatment in Bevacizumab (Bev)-pretreated RAS-mutated (RAS-m) Metastatic Colorectal Cancer (mCRC)** | Zhenyang Liu/ Xiaolin Yang<br>(Changsha, China) | 250eP \| Poster Display: Gastrointestinal tumours, colorectal |
| **Real-world Observational Study of Fruquintinib in Combination with Irinotecan and Capecitabine as Second-line Treatment in Patients with Advanced Colorectal Cancer** | Xiujuan Qu/ Lin Xu <br>(Shenyang, China) | 255eP \| Poster Display: Gastrointestinal tumours, colorectal |
| **Matching-Adjusted Indirect Comparison of Surufatinib versus High-Dose Octreotide LAR in Advanced Extrapancreatic Neuroendocrine Tumors** | Jianming Xu <br>(Beijing, China) | 214P \| Poster Display: Gastrointestinal tumours, colorectal |
| **Efficacy and safety of surufatinib in combination with CAPTEM as conversion therapy in patients with unresectable pancreatic neuroendocrine tumors (pNETs): Data updates from a prospective, open-label study** | Xubao Liu/ Ziyao Wang <br>(Chengdu, China)<br>| 400P \| Poster Display: Gastrointestinal tumours, non-colorectal |

---

Final analysis of long-term results of sovleplenib's ESLIM-01 China Phase III study in in adult patients with chronic primary immune thrombocytopenia will be presented at the 2025 ASH Annual Meeting. Details of the presentation is as follows:

---

| | | |
|:---|:---|:---|
| **Abstract title**<br><BORDER_TOP> | **Presenter/Lead author**<br><BORDER_TOP> | **Presentation details**<br><BORDER_TOP> |
| **2025 ASH Annual Meeting - SPONSORED STUDIES** |  |  |
| **Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia**<br>| Renchi Yang <br>(Tianjin, China) | 843 \| Oral Abstract Session<br>Monday, December 8, 2025<br>15:15 - 15:30 EST <br>Room OCCC - W304EFGH |

---

#### About Fruquintinib
Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors ("VEGFR") -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE<sup>®</sup>. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA<sup>®</sup>.

#### About HMPL-A83
HMPL-A83 is an investigational IgG4-type humanized anti-CD47 monoclonal antibody that exhibits high affinity for CD47. HMPL-A83 blocks CD47 binding to Signal regulatory protein (SIRP) α and disrupts the "do not eat me" signal that cancer cells use to shield themselves from the immune system. HUTCHMED currently retains all rights to HMPL-A83 worldwide.

#### About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS<sup>®</sup>.

------

#### About Surufatinib
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body's immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA<sup>®</sup>. HUTCHMED currently retains all rights to surufatinib worldwide.

#### About Sovleplenib
Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase, also known as Syk. Syk is a major component in B-cell receptor and Fc receptor signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders. HUTCHMED currently retains all rights to sovleplenib worldwide.

#### About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

#### Forward-Looking Statements
*This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED's current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib, the further clinical development for fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib, its expectations as to whether any studies on fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study's inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as camrelizumab and osimertinib as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.*

#### Medical Information
*This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.* 

**CONTACTS**

---

| | |
|:---|:---|
| **Investor Enquiries** | +852 2121 8200 / ir@hutch-med.com |
| **Media Enquiries** |  |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| &nbsp;&nbsp;&nbsp;&nbsp;Ben Atwell / Tim Stamper | &nbsp;&nbsp;&nbsp;&nbsp;+44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| **Panmure Liberum** | *Nominated Advisor and Joint Broker* |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| **Cavendish** | *Joint Broker* |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| **Deutsche Numis** | *Joint Broker* |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |

---

------

## Exhibit 99.2

**Exhibit 99.2**

![Graphic](hcm-20251128xex99d2001.gif)

#### Total Voting Rights
**Hong Kong, Shanghai & Florham Park, NJ — Friday, November 28, 2025:** HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) hereby notifies the market that as at November 28, 2025, the issued share capital of HUTCHMED consisted of 872,169,670 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 872,169,670 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED shares under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For illustrative purposes only, the 872,169,670 ordinary shares would be equivalent to 872,169,670 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 174,433,934 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.

#### About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn. 

**CONTACTS**

---

| | |
|:---|:---|
| **Investor Enquiries** | +852 2121 8200 / <u>ir@hutch-med.com</u> |
| **Media Enquiries** |  |
| FTI Consulting – | +44 20 3727 1030 / <u>HUTCHMED@fticonsulting.com</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;Ben Atwell / Tim Stamper | &nbsp;&nbsp;&nbsp;&nbsp;+44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / <u>HUTCHMED@brunswickgroup.com</u> |
| **Panmure Liberum** | *Nominated Advisor and Joint Broker* |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| **Cavendish** | *Joint Broker* |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| **Deutsche Numis** | *Joint Broker* |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |

---

------